Harrow Health, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark L. Baum
- Full Time Employees
- 373
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1A Burton Hills Boulevard Nashville TN United States of America 37215
- IPO Date
- Sep 28, 2007
- CIK
- 0001360214
- Website
- harrow.com
- Similar Companies
- Business
- Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company that develops, markets, and sells innovative prescription therapies for the eye care market. The company offers a portfolio of branded and compounded ophthalmic products, including ILEVRO (nepafenac ophthalmic suspension) 0.3%, an NSAID for postoperative inflammation and pain following cataract surgery; VEVYE (cyclosporine ophthalmic solution) 0.1%, a nanoemulsion formulation for dry eye disease treatment; and TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, a corticosteroid for vitreoretinal diseases; as well as compounded formulations such as ZERVIATE (cetirizine ophthalmic solution) 0.24% for allergic conjunctivitis and various sterile ophthalmic preparations through its Harrow Equinox subsidiary. Harrow operates primarily in the United States, with headquarters in Nashville, Tennessee, where it was founded in 2012 as a specialty pharmaceutical firm focused on commercial-stage biopharmaceuticals before pivoting to ophthalmology under the leadership of CEO Mark L. Baum. The company serves ophthalmologists, optometrists, and ambulatory surgery centers through direct sales forces and distribution partnerships. In recent developments, Harrow completed the acquisition of the U.S. rights to ILEVRO from Novartis in February 2024, expanding its commercial portfolio and driving revenue growth; launched VEVYE commercially in 2024 following FDA approval as the first and only nanoemulsion cyclosporine solution for dry eye disease, with strong initial uptake reported in Q3 2024 earnings; and in November 2024, announced a strategic commercialization partnership with Visionology for Triesence and other sterile products in key markets, enhancing distribution reach. Additionally, the company raised approximately $80 million through a public offering in mid-2024 to fund product launches and acquisitions, and in late 2024, expanded its manufacturing capacity via the Harrow Equinox facility in North Carolina to meet growing demand for compounded ophthalmics amid FDA compounding regulations. These moves position Harrow for accelerated growth in the $15 billion U.S. ophthalmology market, with no major name changes or reorganizations reported in the last two years.
Company News
Do Options Traders Know Something About Harrow Stock We Don't?
Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research
Harrow Closes Acquisition of TYRVAYA®
Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)
Harrow to Participate in Three Investor Conferences in September
Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow Q2 Earnings Call Highlights
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US